Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (“NSAID”) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as con...
Brand Name : Ketorolac Tromethamine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Concentric Analgesics Data Shows Durable Pain Relief and Earlier Opioid Cessation
Details : CA-008 (vocacapsaicin) a water-soluble prodrug of capsaicin, rapidly releases capsaicin at surgical site triggering the activation of the TRPV1 receptor on pain-specific nerves, producing analgesia.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : $126.0 million
February 06, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : DRI Healthcare Acquisitions
Deal Size : $188.4 million
Deal Type : Agreement
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Details : Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : DRI Healthcare Acquisitions
Deal Size : $188.4 million
Deal Type : Agreement
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Neumentum
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.
Brand Name : NTM-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Neumentum
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Evolution Research Group
Deal Size : Undisclosed
Deal Type : Agreement
Details : The company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials with CA-008 (vocacapsaicin).
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2022
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Evolution Research Group
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : University of Rochester Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin’s benefit to patient recovery and rehabilitation.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2022
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : University of Rochester Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Financing
Details : Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Financing
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : $126.0 million
December 23, 2021
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Rayner Surgical Group Limited
Deal Size : $1,000.0 million
Deal Type : Agreement
Details : As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force. Rayner plans to expand the sales force in both the U.S. and ex-U.S., and further accelerating U.S. market growth of OMIDRIA.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : $125.0 million
December 02, 2021
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Rayner Surgical Group Limited
Deal Size : $1,000.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
